A letter went out alerting doctors about cases of liver damage among patients who took the cancer med in a post-approval study. One patient died from rapidly progressing liver failure and another died from a liver complication called hepatorenal syndrome, according to the letter sent by Genentech and OSI Pharmaceuticals.
Read article at pharmalot.com
Monday, 29 September 2008
Genentech Warns Of Liver Damage From Tarceva
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment